Fig. 7: Effects of statins, gemcitabine and oxaliplatin on cell vitality and migration in PDAC cells and PDAC hERG1 silenced cells.

A Graph of percentage live cells in hERG1 silenced PANC-1, MiaPaCa2 and HEK 293 cells treated for 24 h with IC50 of SIM, FLUVA, LOVA, ATOR, scDb-hERG1-β1 and combination of each statin with scDb-hERG1-β1 is reported. The values of no hERG1 silenced PANC-1 and MiaPaCa2 cells are reported in gray bars. Data are presented as mean values ± s.e.m. (n = 3). B Lateral motility experiments onto FN performed on hERG1 silenced PANC-1 and MiaPaCa2 cells treated with SIM, FLUVA, LOVA, ATOR (at IC50 values for 90 min). The motility is reported as graph of percentage of cell motility; the values of no hERG1 silenced PANC-1 and MiaPaCa2 cells are reported in gray bars. Scale bar: 100 µm. Data are presented as mean values ± s.e.m. (n = 3). C Combination Index curves of PANC-1 and MiaPaCa2 cells CTR and treated with statins, GEM (left panel) and OXA (right panel). We combined the IC25, IC50, IC75 and IC100 of the two chemotherapeutic drugs with the IC25, IC50, IC75 and IC100 of the four statins, deriving these concentrations from the IC50 values shown in Table 1. The Combination Index for all treatments was then calculated. Data are presented as mean values ± s.e.m. (n = 3). D Combination Index curves of PANC-1 and MiaPaCa2 hERG1 silenced cells CTR and treated with statins, GEM (left panel) and OXA (right panel). Data are presented as mean values ± s.e.m. (n = 3). E LDH assay on PANC-1 3D cells treated with SIM (IC50 value), OXA (IC50 and IC25) and scDb-hERG1-β1 (20 µg/ml) for 48 h. The effects of treatment were evaluated through the LDH assay, and the data as shown as percentage of cytotoxicity (see “Materials and methods” for details). Data are presented as mean values ± s.e.m. (n = 3). F LDH assay on hERG1 silenced PANC-1 3D cells (pink bars) and samples transfected with Lipofectamine but no siRNAs, indicated as “Scramble” (light blue bars) PANC-1 3D cells treated with (IC50 value), OXA (IC50 and IC25) and scDb-hERG1-β1 (20 µg/ml) for 48 h. Representative images of 3D cells are reported in Supplementary Fig. 7. Data are presented as mean values ± s.e.m. (n = 3). *P < 0.05, **P < 0.01 and ***P < 0.001 (one-way ANOVA). CTR control, IC inhibitory concentration, SIM Simvastatin, FLUVA Fluvastatin, LOVA Lovastatin, ATOR Atorvastatin, GEM gemcitabine, OXA oxaliplatin.